Related Experiment Videos

Immunotherapy of histiocytosis-X

¹Boston City Hospital, Massachusetts.

Hematology/Oncology Clinics of North America

|March 1, 1987

Abstract:

This article focuses on the interaction of histiocytosis-X and the immunotherapeutic agent, suppression. Studies with this and other agents have presented us with invaluable insights into the nature of histiocytosis-X.

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Autolymphocyte therapy. III. Effective adjuvant adoptive cellular therapy with in vivo anti-tumor specificity against murine melanoma and carcinoma using ex-vivo-activated memory T-lymphocytes.

The Journal of surgical research·1995

Ex vivo activated memory T-lymphocytes as adoptive cellular therapy of human renal cell tumour targets with potentiation by cis-diamminedichloroplatinum(II).

British journal of urology·1995

Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.

International journal of cancer·1995

Ex vivo activated memory T-lymphocytes as adoptive cellular therapy of human soft-tissue sarcoma targets with potentiation by cis-diamminedichloroplatinum(II).

Journal of surgical oncology·1995

Adoptive transfer of ex vivo activated memory T-cells with or without cyclophosphamide for advanced metastatic melanoma: results in 36 patients.

European journal of cancer (Oxford, England : 1990)·1995

Adoptively transferred ex vivo activated memory T cells with cyclophosphamide: effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.

Clinical immunology and immunopathology·1994

See all related articles